BHC
Bausch Health Companies Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$2.11B
5Y Perf.-69.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BHC vs PRGO
Revenue, margins, valuation, and 5-year total return — side by side.
PRGO
Perrigo Company plc
Drug Manufacturers - Specialty & Generic
Market Cap$1.69B
5Y Perf.-77.6%
BHC vs PRGO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BHC | PRGO |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $2.11B | $1.69B |
| Revenue (TTM) | $10.55B | $4.18B |
| Net Income (TTM) | $-1.19B | $-1.82B |
| Gross Margin | 61.7% | 34.2% |
| Operating Margin | 22.9% | -4.1% |
| Forward P/E | 1.3x | 5.8x |
| Total Debt | $21.21B | $3.97B |
| Cash & Equiv. | $1.32B | $532M |
BHC vs PRGO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BHC
PRGO
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Bausch Health Compa… (BHC) | 100 | 30.6 | -69.4% |
| Perrigo Company plc (PRGO) | 100 | 22.4 | -77.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BHC vs PRGO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BHC leads in 6 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Perrigo Company plc is the stronger pick specifically for dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
BHC
Bausch Health Companies Inc.
The Income Pick
BHC carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 2 yrs, beta 1.02
- Rev growth 8.5%, EPS growth 430.8%, 3Y rev CAGR 8.7%
- Lower volatility, beta 1.02, current ratio 1.47x
Best for: income & stability and growth exposure
PRGO
Perrigo Company plc
The Long-Run Compounder
PRGO is the clearest fit if your priority is long-term compounding.
- -76.8% 10Y total return vs BHC's -81.1%
- 9.4% yield; 10-year raise streak; the other pay no meaningful dividend
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BHC | 8.5% revenue growth vs PRGO's -2.8% |
| Value | BHC | Lower P/E (1.3x vs 5.8x) |
| Quality / Margins | BHC | -11.3% margin vs PRGO's -43.5% |
| Stability / Safety | BHC | Beta 1.02 vs PRGO's 1.18 |
| Dividends | PRGO | 9.4% yield; 10-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | BHC | +19.2% vs PRGO's -45.6% |
| Efficiency (ROA) | BHC | -4.5% ROA vs PRGO's -19.8%, ROIC 8.2% vs 3.7% |
BHC vs PRGO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
BHC vs PRGO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLBHCLAGGINGPRGO
PRGOPerrigo Company plc
1leads
BHCBausch Health Compani…
4leads
6 Total Categories
CATEGORYLEADERvs PRGOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BHC6/6
Valuation MetricsMultiples, price ratios, and targets
BHC4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
BHC6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
BHC2/2
Analyst OutlookRatings, price targets, and dividends
PRGO1/1
Income & Cash Flow (Last 12 Months)
BHC leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BHC is the larger business by revenue, generating $10.6B annually — 2.5x PRGO's $4.2B. BHC is the more profitable business, keeping -11.3% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, BHC holds the edge at +10.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | BHCBausch Health Com… | PRGOPerrigo Company p… |
|---|---|---|
| RevenueTrailing 12 months | $10.6B | $4.2B |
| EBITDAEarnings before interest/tax | $3.6B | $58M |
| Net IncomeAfter-tax profit | -$1.2B | -$1.8B |
| Free Cash FlowCash after capex | $990M | $108M |
| Gross MarginGross profit ÷ Revenue | +61.7% | +34.2% |
| Operating MarginEBIT ÷ Revenue | +22.9% | -4.1% |
| Net MarginNet income ÷ Revenue | -11.3% | -43.5% |
| FCF MarginFCF ÷ Revenue | +9.4% | +2.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +10.5% | -7.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -22.7% | -56.4% |
BHC leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
BHC leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, BHC's 6.4x EV/EBITDA is more attractive than PRGO's 7.5x.
| Metric | BHCBausch Health Com… | PRGOPerrigo Company p… |
|---|---|---|
| Market CapShares × price | $2.1B | $1.7B |
| Enterprise ValueMkt cap + debt − cash | $22.0B | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | 13.14x | -1.19x |
| Forward P/EPrice ÷ next-FY EPS est. | 1.31x | 5.82x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 6.37x | 7.53x |
| Price / SalesMarket cap ÷ Revenue | 0.20x | 0.40x |
| Price / BookPrice ÷ Book value/share | 5.63x | 0.58x |
| Price / FCFMarket cap ÷ FCF | 2.10x | 11.63x |
BHC leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
BHC leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
BHC delivers a 5.9% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-51 for PRGO. PRGO carries lower financial leverage with a 1.35x debt-to-equity ratio, signaling a more conservative balance sheet compared to BHC's 56.36x. On the Piotroski fundamental quality scale (0–9), BHC scores 7/9 vs PRGO's 4/9, reflecting strong financial health.
| Metric | BHCBausch Health Com… | PRGOPerrigo Company p… |
|---|---|---|
| ROE (TTM)Return on equity | +5.9% | -50.7% |
| ROA (TTM)Return on assets | -4.5% | -19.8% |
| ROICReturn on invested capital | +8.2% | +3.7% |
| ROCEReturn on capital employed | +10.6% | +4.3% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 4 |
| Debt / EquityFinancial leverage | 56.36x | 1.35x |
| Net DebtTotal debt minus cash | $19.9B | $3.4B |
| Cash & Equiv.Liquid assets | $1.3B | $532M |
| Total DebtShort + long-term debt | $21.2B | $4.0B |
| Interest CoverageEBIT ÷ Interest expense | 1.43x | -7.20x |
BHC leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — BHC and PRGO each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PRGO five years ago would be worth $4,142 today (with dividends reinvested), compared to $2,035 for BHC. Over the past 12 months, BHC leads with a +19.2% total return vs PRGO's -45.6%. The 3-year compound annual growth rate (CAGR) favors BHC at -1.9% vs PRGO's -24.3% — a key indicator of consistent wealth creation.
| Metric | BHCBausch Health Com… | PRGOPerrigo Company p… |
|---|---|---|
| YTD ReturnYear-to-date | -21.6% | -9.6% |
| 1-Year ReturnPast 12 months | +19.2% | -45.6% |
| 3-Year ReturnCumulative with dividends | -5.7% | -56.6% |
| 5-Year ReturnCumulative with dividends | -79.6% | -58.6% |
| 10-Year ReturnCumulative with dividends | -81.1% | -76.8% |
| CAGR (3Y)Annualised 3-year return | -1.9% | -24.3% |
Evenly matched — BHC and PRGO each lead in 3 of 6 comparable metrics.
Risk & Volatility
BHC leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
BHC is the less volatile stock with a 1.02 beta — it tends to amplify market swings less than PRGO's 1.18 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BHC currently trades 65.0% from its 52-week high vs PRGO's 43.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BHCBausch Health Com… | PRGOPerrigo Company p… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.02x | 1.18x |
| 52-Week HighHighest price in past year | $8.69 | $28.44 |
| 52-Week LowLowest price in past year | $4.41 | $9.23 |
| % of 52W HighCurrent price vs 52-week peak | +65.0% | +43.1% |
| RSI (14)Momentum oscillator 0–100 | 52.0 | 53.7 |
| Avg Volume (50D)Average daily shares traded | 1.8M | 3.4M |
BHC leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
PRGO leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates BHC as "Buy" and PRGO as "Hold". Consensus price targets imply 63.1% upside for PRGO (target: $20) vs 41.6% for BHC (target: $8). PRGO is the only dividend payer here at 9.38% yield — a key consideration for income-focused portfolios.
| Metric | BHCBausch Health Com… | PRGOPerrigo Company p… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $8.00 | $20.00 |
| # AnalystsCovering analysts | 38 | 36 |
| Dividend YieldAnnual dividend ÷ price | — | +9.4% |
| Dividend StreakConsecutive years of raises | 2 | 10 |
| Dividend / ShareAnnual DPS | — | $1.15 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
PRGO leads this category, winning 1 of 1 comparable metric.
Key Takeaway
BHC leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). PRGO leads in 1 (Analyst Outlook). 1 tied.
Best OverallBausch Health Companies Inc. (BHC)Leads 4 of 6 categories
Loading custom metrics...
BHC vs PRGO: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is BHC or PRGO a better buy right now?
For growth investors, Bausch Health Companies Inc.
(BHC) is the stronger pick with 8. 5% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Bausch Health Companies Inc. (BHC) offers the better valuation at 13. 1x trailing P/E (1. 3x forward), making it the more compelling value choice. Analysts rate Bausch Health Companies Inc. (BHC) a "Buy" — based on 38 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BHC or PRGO?
On forward P/E, Bausch Health Companies Inc.
is actually cheaper at 1. 3x.
03Which is the better long-term investment — BHC or PRGO?
Over the past 5 years, Perrigo Company plc (PRGO) delivered a total return of -58.
6%, compared to -79. 6% for Bausch Health Companies Inc. (BHC). Over 10 years, the gap is even starker: PRGO returned -76. 8% versus BHC's -81. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BHC or PRGO?
By beta (market sensitivity over 5 years), Bausch Health Companies Inc.
(BHC) is the lower-risk stock at 1. 02β versus Perrigo Company plc's 1. 18β — meaning PRGO is approximately 16% more volatile than BHC relative to the S&P 500. On balance sheet safety, Perrigo Company plc (PRGO) carries a lower debt/equity ratio of 135% versus 56% for Bausch Health Companies Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — BHC or PRGO?
By revenue growth (latest reported year), Bausch Health Companies Inc.
(BHC) is pulling ahead at 8. 5% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Bausch Health Companies Inc. grew EPS 430. 8% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, BHC leads at 8. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — BHC or PRGO?
Bausch Health Companies Inc.
(BHC) is the more profitable company, earning 1. 5% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 1. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BHC leads at 21. 3% versus 8. 1% for PRGO. At the gross margin level — before operating expenses — BHC leads at 60. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is BHC or PRGO more undervalued right now?
On forward earnings alone, Bausch Health Companies Inc.
(BHC) trades at 1. 3x forward P/E versus 5. 8x for Perrigo Company plc — 4. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 63. 1% to $20. 00.
08Which pays a better dividend — BHC or PRGO?
In this comparison, PRGO (9.
4% yield) pays a dividend. BHC does not pay a meaningful dividend and should not be held primarily for income.
09Is BHC or PRGO better for a retirement portfolio?
For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
18), 9. 4% yield). Both have compounded well over 10 years (PRGO: -76. 8%, BHC: -81. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between BHC and PRGO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: BHC is a small-cap deep-value stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while BHC does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(BHC: 10.5% · PRGO: -7.2%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.